Return to Today's science sparks archives

2012-04-02

Figure 2. Neuroendocrine marker immunohistochemistry in large cell neuroendocrine carcinoma. (A) Strong reactivity for synaptophysin and for (B) chromogranin-A in a laryngeal tumor (both 400× magnification).

Figure 2. Neuroendocrine marker immunohistochemistry in large cell neuroendocrine carcinoma. (A) Strong reactivity for synaptophysin and for (B) chromogranin-A in a laryngeal tumor (both 400× magnification).
  • Kusafuka K, Ferlito A, Lewis JS Jr, Woolgar JA, Rinaldo A, Slootweg PJ, Gnepp DR, Devaney KO, Travis WD, Barnes L

  • Oral Oncol. 2012 Mar;48(3):211-5.

2012-04-03

Fig 1a. Representative staining for NRP2 in normal human tissues. Normal Kidney.

Fig 1a. Representative staining for NRP2 in normal human tissues. Normal Kidney.
  • Rushing EC, Stine MJ, Hahn SJ, Shea S, Eller MS, Naif A, Khanna S, Westra WH, Jungbluth AA, Busam KJ, Mahalingam M, Alani RM

  • Hum Pathol. 2012 Mar;43(3):381-9.

2012-04-04

Fig 1. A, Dermatoscopic image of asymmetric pigmented lesion (group A) on lower aspect of the back of a 57-year-old man

Fig 1. A, Dermatoscopic image of asymmetric pigmented lesion (group A) on lower aspect of the back of a 57-year-old man
  • Hashemi P, Pulitzer MP, Scope A, Kovalyshyn I, Halpern AC, Marghoob AA

  • J Am Acad Dermatol. 2012 Mar;66(3):452-62.

2012-04-05

Fig 2. Single-photon emission computed tomography image of cervical sentinel lymph nodes providing more precise anatomic localization in a patient with melanoma of the scalp.

Fig 2. Single-photon emission computed tomography image of cervical sentinel lymph nodes providing more precise anatomic localization in a patient with melanoma of the scalp.
  • Brady MS

  • Future Oncol. 2012 Feb;8(2):191-203.

2012-04-06

Fig 1. Carrión-Rosello Cavernotomes.

Fig 1. Carrión-Rosello Cavernotomes.
  • Martínez-Salamanca JI, Mueller A, Moncada I, Carballido J, Mulhall JP

  • J Sex Med. 2011 Apr 14.

2012-04-09

Fig 1a. Interaction network of C/EBPα and PPARγ derived from Ingenuity pathway analysis.

Fig 1a. Interaction network of C/EBPα and PPARγ derived from Ingenuity pathway analysis.
  • Wu YV, Okada T, DeCarolis P, Socci N, O'Connor R, Geha RC, Joy Somberg C, Antonescu C, Singer S

  • Genes Chromosomes Cancer. 2012 Apr;51(4):313-27.

2012-04-10

Fig 1. Bland–Altman plot. The mean difference between the two measurements is shown with a solid line at 5.49 mm; the lower and upper 95% limits of agreement are the dashed lines at −12.31 mm and 23.30 mm.

Fig 1. Bland–Altman plot. The mean difference between the two measurements is shown with a solid line at 5.49 mm; the lower and upper 95% limits of agreement are the dashed lines at −12.31 mm and 23.30 mm.
  • Lampen-Sachar K, Zhao B, Zheng J, Moskowitz CS, Schwartz LH, Zakowski MF, Rizvi NA, Kris MG, Ginsberg MS

  • Lung Cancer. 2012 Mar;75(3):332-5.

2012-04-11

Fig 3. Increasing second primary malignancy (SPM) rates with time for all malignancies and leukemias are illustrated in patients with well differentiated thyroid cancer (WDTC).

Fig 3. Increasing second primary malignancy (SPM) rates with time for all malignancies and leukemias are illustrated in patients with well differentiated thyroid cancer (WDTC).
  • Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I

  • Cancer. 2011 Oct 1;117(19):4439-46.

2012-04-12

Fig 5. MEMRI demonstrated an altered tonotopic map in Fgf17−/− IC.16- (green) and 40-kHz (red) activity patterns and centroids (small green and red circles) were measured in the IC of Fg17+/− (A) and Fg17−/− (B) mice.

Fig 5. MEMRI demonstrated an altered tonotopic map in Fgf17−/− IC.16- (green) and 40-kHz (red) activity patterns and centroids (small green and red circles) were measured in the IC of Fg17+/− (A) and Fg17−/− (B) mice.
  • Yu X, Nieman BJ, Sudarov A, Szulc KU, Abdollahian DJ, Bhatia N, Lalwani AK, Joyner AL, Turnbull DH

  • Neuroimage. 2011 Jun 1;56(3):1251-8.

2012-04-13

Fig 1. Patient disposition. Values given as number of patients with TPCs in parentheses. Percentages are out of total TPCs. TPC, tunneled pleural catheters.

Fig 1. Patient disposition. Values given as number of patients with TPCs in parentheses. Percentages are out of total TPCs. TPC, tunneled pleural catheters.
  • Suzuki K, Servais EL, Rizk NP, Solomon SB, Sima CS, Park BJ, Kachala SS, Zlobinsky M, Rusch VW, Adusumilli PS

  • J Thorac Oncol. 2011 Apr;6(4):762-7.

2012-04-16

Fig 1. The different mechanisms that lead to polyploidy.

Fig 1. The different mechanisms that lead to polyploidy.
  • Krajcovic M, Overholtzer M

  • Cancer Res. 2012 Apr 1;72(7):1596-601.

2012-04-17

Fig 1. Trafficking and processing of Ras.

Fig 1. Trafficking and processing of Ras.
  • Resh MD

  • Trends Mol Med. 2012 Apr;18(4):206-14.

2012-04-18

Fig 1. By disabling the inhibitory functions of CTLA-4, ipilimumab enhances T-cell activity.

Fig 1. By disabling the inhibitory functions of CTLA-4, ipilimumab enhances T-cell activity.
  • Postow MA, Callahan MK, Wolchok JD

  • Clin Cancer Res. 2012 Apr 1;18(7):1821-3.

2012-04-19

Fig 1. Schematic description of Bioorthogonal Profiling of Protein Methylation (BPPM).

Fig 1. Schematic description of Bioorthogonal Profiling of Protein Methylation (BPPM).
  • Islam K, Bothwell I, Chen Y, Sengelaub C, Wang R, Deng H, Luo M

  • J Am Chem Soc. 2012 Apr 4;134(13):5909-15.

2012-04-20

The overall estimate for the effects of false-positive mammogram results on screening reattendance remains null for Europe, based on our revised meta-analysis of data from over 340,000 women.

The overall estimate for the effects of false-positive mammogram results on screening reattendance remains null for Europe, based on our revised meta-analysis of data from over 340,000 women.
  • Salz T, DeFrank JT, Brewer NT

  • Breast Cancer Res Treat. 2011 May;127(1):229-31.

2012-04-23

Fig 4. Akirin protein is broadly distributed throughout the genome.

Fig 4. Akirin protein is broadly distributed throughout the genome.
  • Nowak SJ, Aihara H, Gonzalez K, Nibu Y, Baylies MK

  • PLoS Genet. 2012 Mar;8(3):e1002547.
Open Access button

2012-04-24

Fig 1. Mutations of epigenetic modifiers identified in patients with myeloproliferative neoplasms (MPNs).

Fig 1. Mutations of epigenetic modifiers identified in patients with myeloproliferative neoplasms (MPNs).
  • Zhang SJ, Abdel-Wahab O

  • Curr Hematol Malig Rep. 2012 Mar;7(1):34-42.

2012-04-25

Fig 3. Coronal whole-body projection images of a patient who had received an oral barium contrast agent before the PET scan.

Fig 3. Coronal whole-body projection images of a patient who had received an oral barium contrast agent before the PET scan.
  • Frey EC, Humm JL, Ljungberg M

  • Semin Nucl Med. 2012 May;42(3):208-18.

2012-04-26

Fig 7. Gradients of lymphatic fluid stasis regulate the expression of adiponectin.

Fig 7. Gradients of lymphatic fluid stasis regulate the expression of adiponectin.
  • Aschen S, Zampell JC, Elhadad S, Weitman E, De Brot M, Mehrara BJ

  • Plast Reconstr Surg. 2012 Apr;129(4):838-47.

2012-04-27

Fig 1. Beta-catenin signalling is not detectable in early nephrogenic tissues, suggesting that Wnt4 acts through a non-canonical pathway during nephrogenesis.

Fig 1. Beta-catenin signalling is not detectable in early nephrogenic tissues, suggesting that Wnt4 acts through a non-canonical pathway during nephrogenesis.
  • Burn SF, Webb A, Berry RL, Davies JA, Ferrer-Vaquer A, Hadjantonakis AK, Hastie ND, Hohenstein P

  • Dev Biol. 2011 Apr 15;352(2):288-98.
Open Access button

2012-04-30

Fig 1. Treatment Landscape for CML PatientsThe figure denotes current and novel therapeutic options for CML patients. Imatinib therapy reduces leukemia bulk cells, but does not deplete leukemia stem cells (LSCs). By contrast, inhibition of Wnt signaling inhibits LSCs but not bulk leukemia cells.

Fig 1. Treatment Landscape for CML PatientsThe figure denotes current and novel therapeutic options for CML patients. Imatinib therapy reduces leukemia bulk cells, but does not deplete leukemia stem cells (LSCs). By contrast, inhibition of Wnt signaling inhibits LSCs but not bulk leukemia cells.
  • Kleppe M, Levine RL

  • Cell Stem Cell. 2012 Apr 6;10(4):351-3.

2012-05-01

Fig 1. Schematic of workflow. Modifications to a previously reported TK screening platform (Chmielecki et al.,2010) were incorporated to take advantage of short-read paired-end sequencing using an ABI SOLiD sequencer.

Fig 1. Schematic of workflow. Modifications to a previously reported TK screening platform (Chmielecki et al.,2010) were incorporated to take advantage of short-read paired-end sequencing using an ABI SOLiD sequencer.
  • Chmielecki J, Peifer M, Viale A, Hutchinson K, Giltnane J, Socci ND, Hollis CJ, Dean RS, Yenamandra A, Jagasia M, Kim AS, Davé UP, Thomas RK, Pao W

  • Genes Chromosomes Cancer. 2012 Jan;51(1):54-65.

2012-05-02

Fig 3. Cell passage – upon day 10 the tissue will appear dramatically thicker with densely packed nuclei and phase-bright ridges.

Fig 3. Cell passage – upon day 10 the tissue will appear dramatically thicker with densely packed nuclei and phase-bright ridges.
  • Chambers SM, Mica Y, Studer L, Tomishima MJ

  • Methods Mol Biol. 2011;793:87-97.

2012-05-03

Fig 1. Location of lymph node packets and boundaries of dissection for extended pelvic lymphadenectomy, including the inferior mesenteric artery superiorly, the genitofemoral nerve laterally, and the node of Cloquet inferiorly.

Fig 1. Location of lymph node packets and boundaries of dissection for extended pelvic lymphadenectomy, including the inferior mesenteric artery superiorly, the genitofemoral nerve laterally, and the node of Cloquet inferiorly.
  • Tarin TV, Power NE, Ehdaie B, Sfakianos JP, Silberstein JL, Savage CJ, Sjoberg D, Dalbagni G, Bochner BH

  • Eur Urol. 2012 May;61(5):1025-30.

2012-05-04

Fig 3. Cumulative incidences of recurrence by stage (treating death from other causes as a competing risk) in patients undergoing preoperative chemotherapy±radiation therapy for gastric and gastrooesophageal junction adenocarcinoma, followed by R0 resection.

Fig 3. Cumulative incidences of recurrence by stage (treating death from other causes as a competing risk) in patients undergoing preoperative chemotherapy±radiation therapy for gastric and gastrooesophageal junction adenocarcinoma, followed by R0 resection.
  • Fields RC, Strong VE, Gönen M, Goodman KA, Rizk NP, Kelsen DP, Ilson DH, Tang LH, Brennan MF, Coit DG, Shah MA

  • Br J Cancer. 2011 Jun 7;104(12):1840-7.

2012-05-07

Fig 4.  Case 2. (B) Re-excision pathology with multiple benign syringomatous proliferations confined to the dermis (H&E, × 10 magnification).

Fig 4.  Case 2. (B) Re-excision pathology with multiple benign syringomatous proliferations confined to the dermis (H&E, × 10 magnification).
  • Liang CA, Busam KJ, Nehal KS

  • Dermatol Surg. 2011 Oct;37(10):1515-8.

2012-05-08

Fig 2. Mutational analysis of the mir-451 hypervariable stem position.

Fig 2. Mutational analysis of the mir-451 hypervariable stem position.
  • Yang JS, Maurin T, Lai EC

  • RNA. 2012 May;18(5):945-57.
Open Access button

2012-05-09

Fig 1. The number of patients evaluated each year for a cystic lesion of the pancreas (blue bars) and the median size (red line) of the lesion at initial visit (1995 to 2010, N = 1,424).

Fig 1. The number of patients evaluated each year for a cystic lesion of the pancreas (blue bars) and the median size (red line) of the lesion at initial visit (1995 to 2010, N = 1,424).
  • Gaujoux S, Brennan MF, Gonen M, D'Angelica MI, DeMatteo R, Fong Y, Schattner M, DiMaio C, Janakos M, Jarnagin WR, Allen PJ

  • J Am Coll Surg. 2011 Apr;212(4):590-600; discussion 600-3.

2012-05-10

Fig 1b. SAHA induces autophagy and LC3 up-regulation in MEF cells.

Fig 1b. SAHA induces autophagy and LC3 up-regulation in MEF cells.
  • Gammoh N, Lam D, Puente C, Ganley I, Marks PA, Jiang X

  • Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6561-5.

2012-05-11

Fig 1. Campaign to improve recognition of back melanoma. Printed with permission.

Fig 1. Campaign to improve recognition of back melanoma. Printed with permission.
  • Geller AC, Swetter SM, Oliveria S, Dusza S, Halpern AC

  • J Am Acad Dermatol. 2011 Nov;65(5 Suppl 1):S87-94.

2012-05-14

Fig 1. Ago1 distribution in Drosophila egg chambers.

Fig 1. Ago1 distribution in Drosophila egg chambers.
  • Azzam G, Smibert P, Lai EC, Liu JL

  • Dev Biol. 2012 May 15;365(2):384-94.

2012-05-15

Fig 1(C). Schematic of the many oncogenic activities attributed to miR-17∼92, with special emphasis on its role as a modulator of cell proliferation.

Fig 1(C). Schematic of the many oncogenic activities attributed to miR-17∼92, with special emphasis on its role as a modulator of cell proliferation.
  • Sage J, Ventura A

  • Genes Dev. 2011 Aug 15;25(16):1663-7.
Open Access button

2012-05-16

Fig 1. The two definitions of the chest wall (CW) as an organ at risk.

Fig 1. The two definitions of the chest wall (CW) as an organ at risk.
  • Mutter RW, Liu F, Abreu A, Yorke E, Jackson A, Rosenzweig KE

  • Int J Radiat Oncol Biol Phys. 2012 Apr 1;82(5):1783-90.

2012-05-17

Fig 1(A). Identification of piRNAs in Aplysia Neurons.

Fig 1(A). Identification of piRNAs in Aplysia Neurons.
  • Rajasethupathy P, Antonov I, Sheridan R, Frey S, Sander C, Tuschl T, Kandel ER

  • Cell. 2012 Apr 27;149(3):693-707.

2012-05-18

Fig 4a. Cells with fragmented mitochondria are resistant to mPTP opening, which can be reversed by restoration of fused morphology.

Fig 4a. Cells with fragmented mitochondria are resistant to mPTP opening, which can be reversed by restoration of fused morphology.
  • Whelan RS, Konstantinidis K, Wei AC, Chen Y, Reyna DE, Jha S, Yang Y, Calvert JW, Lindsten T, Thompson CB, Crow MT, Gavathiotis E, Dorn GW 2nd, O'Rourke B, Kitsis RN

  • Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6566-71.

2012-05-21

Fig 3. Reasons for implant removal versus replacement are depicted.

Fig 3. Reasons for implant removal versus replacement are depicted.
  • Ho A, Cordeiro P, Disa J, Mehrara B, Wright J, Van Zee KJ, Hudis C, McLane A, Chou J, Zhang Z, Powell S, McCormick B

  • Cancer. 2012 May 1;118(9):2552-9.

2012-05-22

Fig 1C. Endometrioid carcinoma exhibiting focal, weak and heterogeneous staining.

Fig 1C. Endometrioid carcinoma exhibiting focal, weak and heterogeneous staining.
  • McCluggage WG, Soslow RA, Gilks CB

  • Histopathology. 2011 Oct;59(4):786-8.

2012-05-23

Fig 1. Survival similar in 3 age cohorts after HCT for CML.

Fig 1. Survival similar in 3 age cohorts after HCT for CML.
  • Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M, Akpek G, Aljurf M, Cahn JY, Cairo M, Chen YB, Cooper B, Deol A, Giralt S, Gupta V, Khoury HJ, Kohrt H, Lazarus HM, Lewis I, Olsson R, Pidala J, Savani BN, Seftel M, Socié G, Tallman M, Ustun C, Vij R, Vindeløv L, Weisdorf D

  • Blood. 2012 Apr 26;119(17):4083-90.

2012-05-24

Fig 1A. Kaplan–Meier estimates of PFS by treatment group in the patients intolerant of previous VEGFr-TKI therapy.

Fig 1A. Kaplan–Meier estimates of PFS by treatment group in the patients intolerant of previous VEGFr-TKI therapy.
  • Bracarda S, Hutson TE, Porta C, Figlin RA, Calvo E, Grünwald V, Ravaud A, Motzer R, Kim D, Anak O, Panneerselvam A, Escudier B

  • Br J Cancer. 2012 Apr 24;106(9):1475-80.

2012-05-25

Figure 2. Images in a 75-year-old man with progressive metastatic prostate cancer starting protocol therapy with abiraterone acetate, an enzyme inhibitor that reduces blood levels of testosterone.

Figure 2. Images in a 75-year-old man with progressive metastatic prostate cancer starting protocol therapy with abiraterone acetate, an enzyme inhibitor that reduces blood levels of testosterone.
  • Kircher MF, Hricak H, Larson SM

  • Mol Oncol. 2012 Apr;6(2):182-95.

2012-05-29

Fig 5. HSV1-tk imaging of cancer dissemination along the sciatic nerve.

Fig 5. HSV1-tk imaging of cancer dissemination along the sciatic nerve.
  • Brader P, Wong RJ, Horowitz G, Gil Z

  • Adv Drug Deliv Rev. 2012 Jun 1;64(8):749-55.

2012-05-30

Fig 2. Semi-quantitative fragment analysis of RT-PCR products revealed the presence of the same alternative transcripts in the patient, her father, and control persons, but at different ratios. Quantification of the three transcripts using the peak height.

Fig 2. Semi-quantitative fragment analysis of RT-PCR products revealed the presence of the same alternative transcripts in the patient, her father, and control persons, but at different ratios. Quantification of the three transcripts using the peak height.
  • Zhang L, Chen L, Bacares R, Ruggeri JM, Somar J, Kemel Y, Stadler ZK, Offit K

  • Breast Cancer Res Treat. 2011 Dec;130(3):1051-6.

2012-05-31

Fig 1. Cumulative incidence of seizure or death without seizure after diagnosis of brain metastasis among patients who did not present with seizure (n = 95).

Fig 1. Cumulative incidence of seizure or death without seizure after diagnosis of brain metastasis among patients who did not present with seizure (n = 95).
  • Goldlust SA, Hsu M, Lassman AB, Panageas KS, Avila EK

  • J Neurooncol. 2012 May;108(1):109-14.

2012-06-01

Scheme 2. Reagents and conditions. (a) TFA, DCM, rt; (b) benzophenone-4-carboxylic acid, EDCI, HOBt, DIPEA, DMF, 52% over 2 steps; (c) LiOH, H2O, DME; (d) TBSCl, Imidazole, DMF; (e) MeOH, 60% over 3 steps; (f) 10, EDCI, HOBt, DIPEA, DMF, 91%; (g) TBAF, THF, 60%.

Scheme 2. Reagents and conditions. (a) TFA, DCM, rt; (b) benzophenone-4-carboxylic acid, EDCI, HOBt, DIPEA, DMF, 52% over 2 steps; (c) LiOH, H2O, DME; (d) TBSCl, Imidazole, DMF; (e) MeOH, 60% over 3 steps; (f) 10, EDCI, HOBt, DIPEA, DMF, 91%; (g) TBAF, THF, 60%.
  • Crump CJ, Am Ende CW, Eric Ballard T, Pozdnyakov N, Pettersson M, Chau DM, Bales KR, Li YM, Johnson DS

  • Bioorg Med Chem Lett. 2012 Apr 15;22(8):2997-3000.

2012-06-04

Figure 2. Waterfall plots of percent change from baseline in measurable tumour at the time of best response

Figure 2. Waterfall plots of percent change from baseline in measurable tumour at the time of best response
  • Yang JC, Shih JY, Su WC, Hsia TC, Tsai CM, Ou SH, Yu CJ, Chang GC, Ho CL, Sequist LV, Dudek AZ, Shahidi M, Cong XJ, Lorence RM, Yang PC, Miller VA

  • Lancet Oncol. 2012 May;13(5):539-48.

2012-06-05

Fig 1. Gli transcriptional activation is dispensable for pancreatic development.

Fig 1. Gli transcriptional activation is dispensable for pancreatic development.
  • Rajurkar M, De Jesus-Monge WE, Driscoll DR, Appleman VA, Huang H, Cotton JL, Klimstra DS, Zhu LJ, Simin K, Xu L, McMahon AP, Lewis BC, Mao J

  • Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):E1038-47.

2012-06-06

Fig 1c. A sagittal view of the original intensity-modulated radiotherapy (IMRT) plan illustrating the dose distribution in the primary site and the upper neck.

Fig 1c. A sagittal view of the original intensity-modulated radiotherapy (IMRT) plan illustrating the dose distribution in the primary site and the upper neck.
  • Damast S, Wolden S, Lee N

  • Head Neck. 2012 Jun;34(6):900-6.

2012-06-07

Fig 1. A 52-year-old woman with biopsy-proven malignant melanoma of the right upper arm developed metastases in the lung, subcutaneous tissues, and the right kidney.

Fig 1. A 52-year-old woman with biopsy-proven malignant melanoma of the right upper arm developed metastases in the lung, subcutaneous tissues, and the right kidney.
  • Lyall A, Vargas HA, Carvajal RD, Ulaner G

  • Clin Nucl Med. 2012 Jun;37(6):629-30.

2012-06-08

Fig 10.1. Multiple processing events generate the mature Shh signaling protein.

Fig 10.1. Multiple processing events generate the mature Shh signaling protein.
  • Buglino JA, Resh MD

  • Vitamins & Hormones 2012; 88:229–252.

2012-06-11

Fig 5. The Fc receptor signals are required for augmented antitumor effects by the combination treatment.

Fig 5. The Fc receptor signals are required for augmented antitumor effects by the combination treatment.
  • Noguchi T, Kato T, Wang L, Maeda Y, Ikeda H, Sato E, Knuth A, Gnjatic S, Ritter G, Sakaguchi S, Old LJ, Shiku H, Nishikawa H

  • Cancer Res. 2012 Apr 1;72(7):1672-1682.

2012-06-12

Fig 1. Effective early infection by GLV-1h68 of human sarcoma cell lines.

Fig 1. Effective early infection by GLV-1h68 of human sarcoma cell lines.
  • He S, Li P, Chen CH, Bakst RL, Chernichenko N, Yu YA, Chen N, Szalay AA, Yu Z, Fong Y, Wong RJ

  • J Surg Res. 2012 Jun 15;175(2):e53-60.

2012-06-13

Figure 1. Probability of freedom from disease recurrence and disease-specific survival after treatment of metastatic NSGCT for patients with CCR and PCR.

Figure 1. Probability of freedom from disease recurrence and disease-specific survival after treatment of metastatic NSGCT for patients with CCR and PCR.
  • Masterson TA, Carver BS, Shayegan B, Feldman DR, Motzer RJ, Bosl GJ, Sheinfeld J

  • Urology. 2012 May;79(5):1079-84.

2012-06-14

Fig 1a. Survival endpoints stratified according to FIGO stage.

Fig 1a. Survival endpoints stratified according to FIGO stage.
  • Cibula D, Abu-Rustum NR, Dusek L, Zikán M, Zaal A, Sevcik L, Kenter GG, Querleu D, Jach R, Bats AS, Dyduch G, Graf P, Klat J, Lacheta J, Meijer CJ, Mery E, Verheijen R, Zweemer RP

  • Gynecol Oncol. 2012 Mar;124(3):496-501.

2012-06-15

In the simulation, PSCBS compares favorably to established methods.

In the simulation, PSCBS compares favorably to established methods.
  • Olshen AB, Bengtsson H, Neuvial P, Spellman PT, Olshen RA, Seshan VE

  • Bioinformatics. 2011 Aug 1;27(15):2038-2046.

2012-06-18

Fig 1. Overall survival from start of MEC or ME by type of treatment.

Fig 1. Overall survival from start of MEC or ME by type of treatment.
  • Trifilio SM, Rademaker AW, Newman D, Coyle K, Carlson-Leuer K, Mehta J, Altman J, Frankfurt O, Tallman MS

  • Leuk Res. 2012 Apr;36(4):394-6.

2012-06-19

Fig 1. Overall survival (A) and cancer specific survival (B) curves for patients with SqD and SCC treated with RCPLND. TCC, transitional cell carcinoma.

Fig 1. Overall survival (A) and cancer specific survival (B) curves for patients with SqD and SCC treated with RCPLND. TCC, transitional cell carcinoma.
  • Ehdaie B, Maschino A, Shariat SF, Rioja J, Hamilton RJ, Lowrance WT, Poon SA, Al-Ahmadie HA, Herr HW

  • J Urol. 2012 Jan;187(1):74-9.

2012-06-20

Fig 1. A single leading-strand template CPD provides only a transient block to replisome progression.

Fig 1. A single leading-strand template CPD provides only a transient block to replisome progression.
  • Yeeles JT, Marians KJ

  • Science. 2011 Oct 14;334(6053):235-8.

2012-06-21

Fig 1. Recurrence-free survival comparing open partial nephrectomy versus minimally invasive partial nephrectomy.

Fig 1. Recurrence-free survival comparing open partial nephrectomy versus minimally invasive partial nephrectomy.
  • Sprenkle PC, Power N, Ghoneim T, Touijer KA, Dalbagni G, Russo P, Coleman JA

  • Eur Urol. 2012 Mar;61(3):593-9.

2012-06-22

Fig 4G. PRK2 function is RhoA-dependent, kinase-dependent, and requires its C2-like domain. (G) Cells were fixed and stained with anti-ZO-1 (green) and Hoechst stain (blue).

Fig 4G. PRK2 function is RhoA-dependent, kinase-dependent, and requires its C2-like domain. (G) Cells were fixed and stained with anti-ZO-1 (green) and Hoechst stain (blue).
  • Wallace SW, Magalhaes A, Hall A

  • Mol Cell Biol. 2011 Jan;31(1):81-91.

2012-06-25

Secondary structure schematic of the 52-nucleotide sensing domain of the T. petrophila fluoride riboswitch used in this study.

Secondary structure schematic of the 52-nucleotide sensing domain of the T. petrophila fluoride riboswitch used in this study.
  • Ren A, Rajashankar KR, Patel DJ

  • Nature. 2012 May 13;486(7401):85-9.

2012-06-26

Fig 1. SUVmax (A) and average SUV (B) in muscle groups and liver and spine background regions in 3 patient groups. CI = confidence interval.

Fig 1. SUVmax (A) and average SUV (B) in muscle groups and liver and spine background regions in 3 patient groups. CI = confidence interval.
  • Lyall A, Capobianco J, Strauss HW, Gonen M, Schöder H

  • J Nucl Med. 2012 Jun;53(6):917-21.

2012-06-27

Fig 1. Gap-junction-mediated electrical coupling between sister excitatory neurons in neonatal neocortical ontogenetic columns.

Fig 1. Gap-junction-mediated electrical coupling between sister excitatory neurons in neonatal neocortical ontogenetic columns.
  • Yu YC, He S, Chen S, Fu Y, Brown KN, Yao XH, Ma J, Gao KP, Sosinsky GE, Huang K, Shi SH

  • Nature. 2012 May 2;486(7401):113-7.

2012-06-28

Fig 1a. Network analysis connecting those gene products genetically implicated in human cell transformation.

Fig 1a. Network analysis connecting those gene products genetically implicated in human cell transformation.
  • Miller JP, Yeh N, Hofstetter CP, Keskin D, Goldstein AS, Koff A

  • J Biol Chem. 2012 Jun 8;287(24):19775-85.

2012-06-29

Fig 1. Two Paths for UV-Induced Squamous Cell Carcinoma in a well-established process.

Fig 1. Two Paths for UV-Induced Squamous Cell Carcinoma in a well-established process.
  • Vanharanta S, Massagué J

  • Cell. 2012 Jun 8;149(6):1179-81.